voltage dependent anion channel 3Genealiases: HD-VDAC3 · VDAC-3
Q-omics provides the consensus-scored VDAC3 profile across patient tissues and cancer cell-line models. VDAC3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, VDAC3 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, VDAC3 protein abundance shows 33,518 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, THCA, and GBM as cancer lineages where VDAC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VDAC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VDAC3 survival associations across molecular data types. VDAC3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VDAC3 RNA expression–survival associations across cancer types. High VDAC3 expression shows unfavorable associations in LUAD, ACC, MESO, KICH, LIHC and ESCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for VDAC3 RNA expression.
This table summarizes VDAC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 13. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VDAC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VDAC3 shows lower tumor expression in THCA and higher tumor expression in LIHC, UCEC, LUSC, BRCA and CHOL. The THCA box plot shows higher VDAC3 RNA expression in normal versus tumor tissue (log2 FC = −1.496, t-test p < 0.001).
This table shows molecular features associated with VDAC3 in patient tissues and cancer cell lines. In patient samples, VDAC3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, VDAC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
